How Much Does Genetic Testing for Mental Health Medication Cost?
The short answer: for most patients, somewhere between $0 and around $330.
The longer answer is more useful, because that range hides a lot. Whether you land at the bottom or the top depends on your insurer, your diagnosis, your treatment history, who orders the test, and which specific panel gets run.
This guide covers what you'd actually pay, why coverage varies so much between insurers, and — importantly — the questions worth asking before anyone swabs your cheek.
The Price Range, Plainly
Self-pay: The most widely used psychiatric pharmacogenomic test publishes a self-pay price of $330, with income-based financial assistance and interest-free payment plans available for those who qualify. Other clinical panels generally fall in the 250–600 range when paid out of pocket.
The list price is much higher — often quoted around $2,000 — but almost nobody pays it. Testing companies cap patient responsibility well below list.
With commercial insurance: anywhere from $0 to the self-pay cap, depending on your plan, your deductible status, and whether your plan covers multi-gene panels at all.
With Medicare or Medicaid: frequently $0 — but with real conditions attached, which we'll get into below.
Why Coverage Varies So Much
This is the part almost no one explains, and it's the key to understanding your own situation.
Insurers disagree about the evidence.
Pharmacogenomic testing isn't one thing. There's a meaningful distinction between:
Single-gene or narrow-panel testing — for example, looking at CYP2C19 and CYP2D6, the enzymes with the best-established influence on how you process common antidepressants
Combinatorial panels — larger multi-gene tests that run an algorithm across many genes and sort medications into color-coded categories
Payers treat these differently, because the evidence behind them differs.
Medicare's MolDX Local Coverage Determination — the policy governing pharmacogenomic testing coverage — is explicitly limited. It covers combinatorial panels in narrow circumstances, and covers certain tests for patients in whom a two-gene panel of CYP2C19 and CYP2D6 is reasonable and necessary, when ordered by a psychiatrist. The policy's own reasoning notes that published studies on combinatorial panels have had significant shortcomings, including failing to meet their primary endpoints.
UnitedHealthcare's Medicare Advantage policy goes further still, stating that combinatorial panels are not reasonable and necessary due to insufficient evidence of efficacy for psychiatric indications.
On the commercial side, UnitedHealthcare updated its commercial policy effective January 1, 2025, under which multi-gene pharmacogenomic panels are generally not covered for commercial plan members.
What this means for you: the confident "$0 with Medicare!" you'll see on testing company websites is accurate for many patients — but it's conditional, not automatic. Whether you qualify depends on your diagnosis, your documented treatment history, who orders the test, and which panel is run.
What to Expect by Coverage Type
Medicare (Part B and Medicare Advantage)
Many patients pay $0. But coverage requires meeting the criteria in the applicable Local Coverage Determination — typically a documented psychiatric diagnosis, a history of inadequate response or intolerance to medication, and appropriate ordering and documentation.
The part nobody warns you about: if Medicare determines the test is non-covered in your case, your clinician must have you sign an Advance Beneficiary Notice (ABN) before the test is processed. By signing, you're agreeing to pay the full cost and will be billed accordingly.
Read that form. It is not a formality. If someone hands it to you without explanation, ask what your estimated cost is before signing.
Medicaid / MassHealth
Medicaid programs frequently cover pharmacogenomic testing at no patient cost when clinical criteria are met, and testing companies commonly report $0 as the typical Medicaid out-of-pocket. Coverage policies are state-specific, so verify your own situation with MassHealth or your managed care plan rather than assuming.
Commercial insurance
The most variable category. Some plans cover multi-gene panels for specific indications such as treatment-resistant depression. Others — including UnitedHealthcare's commercial plans under its current policy — generally do not cover multi-gene panels at all.
Your out-of-pocket also depends on where you are in your deductible year. The same test can cost $0 in November and several hundred dollars in January.
Uninsured or choosing not to use insurance
Self-pay pricing applies, capped at $330 for the most widely used test. Income-based financial assistance programs and interest-free payment plans are available from major testing companies.
What About Using My 23andMe or AncestryDNA Data?
Several services offer to analyze raw data from consumer ancestry tests for 19–59 and produce a pharmacogenomic-style report.
It's understandable why this appeals. It's also worth being clear about what you're getting.
Consumer ancestry tests are not designed or validated for clinical prescribing decisions. They use genotyping approaches that can miss variants clinical panels detect, and their raw data files carry known accuracy limitations for individual variants. A report generated from that data is not equivalent to a clinical laboratory result, and most prescribers will not — and should not — change your medication based on it.
If you're curious, there's no harm in looking. But don't mistake it for the clinical test, and don't bring it to your prescriber expecting it to substitute.
Is It Worth the Cost?
An honest answer depends on your situation.
Testing is more likely to be worth it if:
You've had severe or unusual side effects at standard or low doses
You've failed multiple medication trials without a clear explanation
You're taking several medications and interactions are a concern
You're considering a medication with a narrow safety margin
A close family member had an unusual reaction to a psychiatric medication
Testing is less likely to be worth it if:
You're starting your first antidepressant with no complicating history
Your current medication is working reasonably well
You're expecting the test to identify one medication guaranteed to work
That last point matters. Pharmacogenomic testing tells you useful things about how your body processes medications. It does not predict which medication will lift your depression — the genes associated with therapeutic response aren't currently supported for clinical prescribing decisions. Paying $330 expecting an answer the test can't give is how people end up disappointed.
Weigh it against what you're already spending. Multiple failed medication trials mean repeated appointments, repeated copays, and — usually the largest hidden cost — months of reduced functioning at work and at home. Against that, a one-time cost capped at $330 looks different.
Questions to Ask Before You Get Tested
Bring this list to your appointment.
What will this test actually tell us, given my specific history?
Which panel are you ordering, and which genes does it cover?
Will my insurance cover it — and can your office verify before we order?
What's my estimated out-of-pocket cost?
Will I be asked to sign an Advance Beneficiary Notice? (If yes, what does it commit me to?)
Will we review the results together, or will they just be sent to me?
Which parts of the report will you act on, and which will you disregard?
If a provider can't answer questions 3 and 4 before ordering, ask them to find out first. A surprise bill is avoidable.
How We Handle This at Awaken Mind Center
We verify coverage before ordering. Not after.
When a patient at our Norwood or Braintree office is considering pharmacogenomic testing, our team checks benefits with their specific plan and gives an estimated out-of-pocket cost first. If coverage looks unlikely and the self-pay cost isn't right for that patient's situation, we say so — and we talk about whether testing is even the highest-value next step.
Sometimes it isn't. For someone starting their first antidepressant, a careful diagnostic evaluation and proper dose titration will usually do more than a genetic test would. We'd rather tell you that than take the order.
Frequently Asked Questions
What's the maximum I could pay?
For the most widely used psychiatric pharmacogenomic test, the published self-pay cap is $330, with financial assistance available for those who qualify. The main risk of paying more is signing an Advance Beneficiary Notice without understanding it — ask for a cost estimate first.
Is genetic testing covered by insurance in Massachusetts?
Often, but it depends on your carrier and plan. Medicare and Medicaid patients frequently pay nothing when criteria are met. Commercial coverage varies significantly and has tightened at some insurers. Verify with your own plan.
Why did my friend pay $0 and I was quoted more?
Most likely a different insurer, a different deductible position, a different diagnosis or documented history, or a different panel being ordered. All four affect the outcome.
Do I need a psychiatrist to order it?
For some Medicare coverage pathways, yes — the applicable policy specifies psychiatrist ordering for certain covered tests. Requirements vary by payer and policy.
Does insurance cover repeat testing?
Generally no. Your DNA doesn't change, so the test is normally a one-time expense. Keep your report.
Can I get it done without insurance involved at all?
Yes. Self-pay is an option, and for patients whose estimated out-of-pocket exceeds the self-pay price, it's often the cheaper route.
Is a cheaper test just as good?
Not necessarily. Price differences often reflect which genes are covered and whether the lab is clinically certified. A cheaper panel covering fewer genes may still be appropriate — that's a clinical judgment worth discussing rather than a pure price comparison.
Find Out What It Would Cost You
Rather than guessing, ask. We verify pharmacogenomic testing coverage with your specific plan before ordering, at both our Norwood and Braintree locations.
Call: 617-729-2369 or book a consultation.
